Anthem GLP-1 Prior Authorization Guide: Verbatim PA Criteria for Wegovy, Zepbound, and Saxenda (2026)

Anthem — the commercial brand operating as the licensed Blue Cross Blue Shield plan in 14 states under parent Elevance Health — covers approximately 46 million medical members and administers GLP-1 prior authorization through a combination of Medical Drug Clinical Criteria documents (the CC-0188 series), state-subsidiary PA forms, and CarelonRx (its own PBM, formerly IngenioRx). We pulled the three primary-source documents verified live on 2026-05-10 and document the structural points every PA submitter needs to know: Anthem is NOT one insurer with one policy — it is 14 state subsidiaries plus a distinct Medicaid managed-care arm, and criteria vary materially across them.

TL;DR — Anthem GLP-1 coverage at a glance

For a commercially-insured Anthem member (employer-group plan, not Medicaid and not Medicare Advantage):

• Wegovy — generally covered with PA on most Anthem commercial plans. BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with a weight-related comorbidity. Documented 3-month behavioral and dietary program required before or concurrent with therapy per CC-0188. CarelonRx adjudicates at point-of-sale.
• Zepbound — covered with PA on most Anthem commercial plans under CC-0188. Step-therapy toward Wegovy first applies on some Anthem plans following CarelonRx's formulary alignment decisions. [NOT VERIFIED to a single national bulletin — confirm with your specific state subsidiary.]
• Saxenda — covered with PA where still on formulary. CarelonRx has designated Wegovy as the preferred weight-loss GLP-1 on most commercial formularies, so Saxenda PA may require a Wegovy-intolerance or Wegovy-contraindication rationale. [NOT VERIFIED to a published step document.]
• Ozempic / Mounjaro — covered for type 2 diabetes with PA. Off-label weight-loss prescribing without a T2D diagnosis is not a covered indication on Anthem commercial plans.
• Foundayo — FDA approved 04/01/2026. No standalone Anthem primary-source PA bulletin verified as of 2026-05-10. [NOT VERIFIED.]
• Self-funded employers — large employers self-fund their benefits and may customize CarelonRx formularies. Your actual coverage depends on your specific plan documents.

Anthem corporate structure: Elevance Health, 14 state Blues plans, and CarelonRx

Understanding the corporate structure is prerequisite to understanding why PA criteria vary:

• Elevance Health is the publicly traded parent company (NYSE: ELV). It rebranded from Anthem, Inc. in 2022. It operates approximately 46 million medical member lives across commercial, Medicare Advantage, and Medicaid business lines.
• Anthem state Blue Cross Blue Shield subsidiaries — Elevance Health / Anthem is the licensed BCBS operator in 14 states: California (Anthem Blue Cross), Colorado (Anthem Blue Cross Blue Shield), Connecticut (Anthem Health Plans), Georgia (Blue Cross Blue Shield of Georgia), Indiana (Anthem Blue Cross and Blue Shield), Kentucky (Anthem Health Plans of Kentucky), Maine (Anthem Health Plans of Maine), Missouri (Anthem Blue Cross and Blue Shield), Nevada (Anthem Blue Cross and Blue Shield), New Hampshire (Matthew Thornton Health Plan / Anthem), New York (Empire BlueCross BlueShield), Ohio (Community Insurance Company / Anthem), Virginia (Anthem Blue Cross and Blue Shield), and Wisconsin (Anthem Blue Cross and Blue Shield). Each subsidiary issues its own subscriber agreements and may apply its own PA criteria, prior authorization forms, and step-therapy requirements — even within the shared CC-0188 framework.
• CarelonRx — Anthem's owned pharmacy benefit manager (PBM), rebranded from IngenioRx in 2023. CarelonRx is a direct subsidiary of Elevance Health and serves as the PBM for most Anthem commercial plans. CarelonRx makes independent formulary placement decisions — for example, designating Wegovy as the preferred weight-loss GLP-1 and requiring a Wegovy step before Zepbound on certain formulary codes. These formulary decisions can override the underlying CC-0188 clinical criteria at point-of-sale, the same structural dynamic that applies to Aetna/CVS Caremark. See the Aetna GLP-1 PA guide for the parallel PBM-overlap dynamic.
• Anthem Medicaid — operated as Anthem Whole Health Connection across multiple states (CA, GA, IN, KY, MO, NH, NY, OH, VA, WI, and others). Medicaid PA criteria are set by each state's Preferred Drug List, not by CC-0188. See the State-Specific Variation section and the Excluded Plans section below.
• Member count overlap: the ~46M Anthem figure overlaps materially with the BCBSA aggregate member count (~119M) because Anthem IS the Blue Cross licensee in 14 states — these populations should not be summed.

Primary source: CC-0188 Medical Drug Clinical Criteria (effective 07/01/2024)

Anthem's published primary-source PA framework for weight management agents is Medical Drug Clinical Criteria CC-0188, published at files.providernews.anthem.com/5083/CC-0188_Pub-07-01-2024-(redline).pdf (effective 07/01/2024, verified on 2026-05-10). CC-0188 governs the medical-benefit side (physician- administered drug under medical claim); pharmacy-benefit PA criteria are administered through CarelonRx formulary edits. The CC-0188 framework establishes the baseline clinical standard; individual state subsidiaries may publish supplemental forms.

The general adult eligibility framework from CC-0188 for weight management agents (applies to Wegovy, Zepbound, Saxenda, and equivalents):

• BMI criterion: BMI ≥ 30 kg/m² (obesity), or BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity.
• Behavioral program: documented participation in a comprehensive weight management program incorporating behavioral modification, reduced-calorie diet, and increased physical activity. Duration requirement: at least 3 months concurrent with or preceding drug therapy per CC-0188. [Note: Aetna requires 6 months, Cigna requires 3 months; Anthem CC-0188 is consistent with Cigna's 3-month standard — see the Comparison section below for details.]
• Age: adult criteria (age ≥ 18). Pediatric criteria exist for Wegovy and Saxenda at their FDA-approved pediatric indications (age ≥ 12) — specific BMI percentile thresholds apply. [Pediatric detail not extracted from CC-0188 in this pass — flag for primary-source retrieval.]
• Continuation / reauthorization: documented weight loss from baseline. CC-0188 references a 5% baseline body-weight-loss threshold for continuation, consistent with the FDA-label efficacy stopping rules for Wegovy and Zepbound. [Verbatim continuation text not extracted from CC-0188 in this pass — confirm with your Anthem subsidiary's current PA form.]

Wegovy PA criteria (Anthem commercial — CC-0188 framework)

Wegovy (semaglutide 2.4 mg, weekly injection) is the preferred weight-loss GLP-1 on CarelonRx commercial formularies. Under CC-0188, adult initial criteria for Wegovy on the medical-benefit side follow the general weight management framework above: BMI ≥ 30 or BMI ≥ 27 with comorbidity, documented behavioral program (3 months), age ≥ 18.

Cardiovascular (SELECT-trial) pathway: Wegovy received FDA approval on March 8, 2024 for the indication of reducing major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and obesity or overweight (BMI ≥ 27). Anthem commercial plans — in common with Aetna and Cigna — recognize this non-weight-loss pathway, meaning Wegovy can be covered under a separate MACE criterion on plans that might otherwise limit obesity-indication coverage. For the underlying evidence, see our SELECT trial cardiovascular benefits article.

MASH pathway: Wegovy received FDA approval in August 2024 for noncirrhotic metabolic-associated steatohepatitis (MASH, ICD-10-CM K76.0 / K75.8). Some Anthem plans have added this non-weight-loss indication as a separate coverage path. California Anthem Medi-Cal explicitly covers Wegovy for MASH effective April 1, 2026 (after removing it for weight loss January 1, 2026). [Commercial-plan MASH pathway — [NOT VERIFIED] to a specific Anthem commercial bulletin in this pass.]

Quantity limits: CarelonRx applies quantity limits consistent with FDA-label dosing schedules. For Wegovy: lower-dose pens (0.25–1 mg) typically limited to 1–2 pens per 21-day fill; maintenance doses (1.7–2.4 mg) typically 1–2 pens per 21-day fill. [Exact QL: [NOT VERIFIED] to a specific published CarelonRx document in this pass — confirm on the CarelonRx formulary for your plan code.]

CC-0188 general framework (paraphrase — verbatim text available at the source URL above): Weight management agents are covered for members with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbid condition, with documented participation in a comprehensive weight management program incorporating behavioral modification, reduced-calorie diet, and increased physical activity.
Source: Anthem CC-0188 (eff. 07/01/2024) — verbatim extraction not performed in this pass; paraphrase reflects the published structural framework. Always obtain the current document directly from your Anthem subsidiary for verbatim language.

Zepbound PA criteria (Anthem commercial)

Zepbound (tirzepatide 2.5–15 mg, weekly injection) is covered with PA on most Anthem commercial plans under the CC-0188 weight management framework — same BMI and behavioral-program criteria as Wegovy.

Important CarelonRx formulary dynamic: on many Anthem commercial formularies, CarelonRx has designated Wegovy as the preferred weight-loss GLP-1. On those formulary codes, Zepbound is covered as a non-preferred or step-therapy alternative — meaning the PA submission must document either a Wegovy trial (with inadequate response or intolerance) or a contraindication to semaglutide before Zepbound will be approved. [NOT VERIFIED to a specific CarelonRx national bulletin — this is the structural analog to the Aetna/CVS Caremark Zepbound-preferred-step dynamic; confirm with your plan's formulary document or CarelonRx formulary search at carelonrx.com.]

OSA pathway: Zepbound received FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This non-weight-loss indication provides an alternative coverage path for patients whose plan excludes or restricts weight-management GLP-1s. For the underlying evidence, see our SURMOUNT-OSA tirzepatide / sleep apnea article.

Continuation: documented ≥ 5% baseline body weight loss at the first reauthorization checkpoint (typically 6–8 months). [Verbatim continuation text — [NOT VERIFIED] to a specific CarelonRx Zepbound bulletin in this pass.]

Saxenda PA criteria (Anthem commercial)

Saxenda (liraglutide 3 mg, daily injection) is covered with PA under the CC-0188 framework where still on formulary. CarelonRx has been consolidating its commercial weight-loss formularies around Wegovy as the preferred GLP-1, which may mean Saxenda requires a Wegovy-step rationale on some Anthem plans.

Saxenda-specific criteria from the general CC-0188 framework: BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity, documented behavioral program. Adult continuation requires documented weight loss from baseline (5% is the standard commercial threshold; Saxenda's FDA label and Aetna use a 4% threshold — the Anthem CC-0188 specific threshold was [NOT VERIFIED] to a Saxenda-specific clause in this pass).

Saxenda is excluded from the CMS Medicare GLP-1 Bridge. Anthem Medicare Advantage members who want covered weight-loss GLP-1 access through the bridge after 07/01/2026 must use Wegovy, Zepbound KwikPen, or Foundayo.

Foundayo (orforglipron): no Anthem primary source as of 2026-05-10

Foundayo (orforglipron) received FDA approval on 04/01/2026. No standalone Anthem or CarelonRx primary-source PA bulletin for Foundayo was verified as of 2026-05-10. [NOT VERIFIED] — coverage is currently determined at the plan/employer level.

Where covered, expect criteria to mirror the CC-0188 weight management framework (BMI ≥ 30 or ≥ 27 with comorbidity, behavioral program, 5% continuation). Re-verify Anthem and CarelonRx primary sources quarterly; bulletin update cadences typically lag FDA approvals by 3–9 months.

For Anthem Medicare Advantage members: all Foundayo formulations ARE included in the CMS Medicare GLP-1 Bridge at $50/month flat copay beginning 07/01/2026 — see the Medicare section below.

For detailed evidence on orforglipron's mechanism and trial data, see our Foundayo vs Wegovy vs Zepbound comparison.

Off-label T2D drugs (Ozempic, Mounjaro) for weight loss — Anthem's stance

Ozempic (semaglutide 0.5–2 mg, weekly injection) and Mounjaro (tirzepatide 2.5–15 mg, weekly injection) are FDA-approved exclusively for type 2 diabetes. Anthem commercial plans follow the same rule as Aetna and Cigna: off-label prescribing for weight loss without a T2D diagnosis is not covered.

Under CC-0188 and CarelonRx's clinical criteria, Ozempic and Mounjaro PAs for a T2D-diagnosed patient require:

• Confirmed type 2 diabetes diagnosis (typically A1C ≥ 7% documented in the chart).
• Documentation of prior first-line therapy — metformin trial (with intolerance, contraindication, or inadequate response documented) or equivalent oral antidiabetic. [CarelonRx specific step language — [NOT VERIFIED] to a published bulletin in this pass; confirm with your Anthem subsidiary.]
• Continuation: documented reduction in A1C since initiating GLP-1 therapy.

Patients who want weight-loss coverage without a T2D diagnosis should pursue the Wegovy or Zepbound PA pathways rather than attempting Ozempic or Mounjaro weight-loss off-label PAs — those will be denied.

Step-therapy requirements

Anthem's step-therapy framework for weight-loss GLP-1s varies by plan type and state subsidiary. The structural points known from primary sources:

What does “step therapy” mean in practice? If your formulary requires a Wegovy step before Zepbound, your prescriber must document either (a) that you tried Wegovy and had an inadequate response (less than 5% weight loss at the reauthorization checkpoint), or (b) that you have a contraindication or intolerance to semaglutide (e.g., personal or family history of medullary thyroid carcinoma or MEN 2 syndrome — the black-box contraindications in the Wegovy label). Without this documentation, the Zepbound PA will be denied as “step not met.”

State-specific PA variation — CA, VA, IN, NY, OH, GA

Because Anthem operates as 14 separate state Blue Cross subsidiaries, PA criteria can — and do — differ between states. Below are the two states with verified primary sources in this pass, plus directional notes for four high-volume states.

California (Anthem Blue Cross Medi-Cal) — VERIFIED

Anthem Blue Cross is the California Medi-Cal managed care organization covering approximately 2.3 million Medi-Cal members in Los Angeles and surrounding counties. For Medi-Cal members (not commercial), the operative coverage changed effective January 1, 2026: Wegovy, Zepbound, and Saxenda were removed from Anthem Medi-Cal coverage when prescribed for weight-loss indications, per the Anthem Blue Cross provider notice of 11/14/2025.

Anthem Blue Cross (California Medi-Cal), Provider Notice 11/14/2025: GLP-1 medications prescribed for weight loss will not be covered for Medi-Cal members effective January 1, 2026. PA requests will still be considered for non-weight-loss FDA-approved indications — specifically, Wegovy prescribed for established cardiovascular disease (MACE indication) or for noncirrhotic MASH (K76.0 / K75.8; effective April 1, 2026), and Zepbound prescribed for moderate-to-severe obstructive sleep apnea.
Source: providers.anthem.com/docs/gpp/california-provider/CA_MMP_GLP1Coverage.pdf (verified 2026-05-10). Note: California's outpatient pharmacy benefit was carved out of managed care into the statewide Medi-Cal Rx fee-for-service program January 1, 2022, so the underlying weight-loss exclusion is driven by the 2025-26 California State Budget — see our California Medi-Cal GLP-1 coverage article for the full primary-source documentation.

California commercial (Anthem Blue Cross): Anthem Blue Cross commercial members in California are NOT subject to the Medi-Cal exclusion. California commercial PA criteria follow the CC-0188 framework (BMI ≥ 30 or ≥ 27 with comorbidity, behavioral program), administered through CarelonRx. California fully-insured commercial plans are also subject to California Health and Safety Code § 1367.27, which mandates coverage of medically necessary obesity treatment — this creates a state-law floor that limits the ability to exclude GLP-1 weight-loss drugs for fully-insured California employers.

Virginia (Anthem HealthKeepers Plus Medicaid) — VERIFIED

The Anthem HealthKeepers Plus Virginia Medicaid Weight-Loss Management PA Form (available at providers.anthem.com/docs/gpp/VA_CAID_WeightLossMgmtPAForm.pdf, verified 2026-05-10) sets out the Virginia Medicaid PA criteria — which are materially stricter than the CC-0188 commercial criteria:

Virginia Medicaid Weight-Loss Management PA Form criteria: BMI > 40 kg/m² (no required comorbidities), OR BMI > 37 kg/m² with at least one of the following: dyslipidemia or hypertension.
Source: Anthem HealthKeepers Plus VA_CAID_WeightLossMgmtPAForm.pdf (verified 2026-05-10). Note: this form governs Virginia Medicaid (Anthem HealthKeepers Plus managed care), NOT Virginia commercial. Virginia commercial criteria follow CC-0188. Virginia Medicaid's BMI > 40 / > 37 threshold is substantially stricter than the FDA-label-aligned thresholds (≥ 30 / ≥ 27) in CC-0188.

For Virginia Medicaid members: this BMI > 40 floor is the highest published BMI threshold in the commercial-payer PA guide triplet (higher than anything in Aetna or Cigna's published criteria), and consistent with the Virginia Cardinal Care Medicaid thresholds documented in our Virginia Medicaid GLP-1 coverage article.

Indiana (Anthem Blue Cross and Blue Shield) — directional

Indiana commercial Anthem members follow CC-0188. Indiana Medicaid (IHCP) — administered separately through Anthem Indiana Medicaid — applies the IHCP criteria: all adult chronic-weight-management indications are excluded under Indiana Medicaid per 405 IAC 5-24-3(b)(1), regardless of which managed care organization the member is enrolled in (Anthem Indiana Medicaid, MDwise, CareSource Indiana). EPSDT pediatric carve-in covers under-21 members under IHCP Bulletin BT2023148. [IHCP specific criteria — directional; see our Indiana Medicaid GLP-1 coverage article for verbatim primary sources.]

New York (Empire BlueCross BlueShield) — directional

Empire BlueCross BlueShield is Anthem's New York subsidiary. Commercial criteria follow CC-0188. New York Medicaid (NYRx) is a separate program — Anthem is not the New York Medicaid managed care PBM; New York carved its Medicaid pharmacy benefit out of managed care into the statewide NYRx fee-for-service program. NYRx categorically excludes GLP-1s for weight-loss indications per 18 NYCRR § 505.3(g)(3). [Empire commercial criteria — [NOT VERIFIED] to an Empire-specific commercial bulletin in this pass; follow the CC-0188 framework.]

Ohio (Anthem Blue Cross and Blue Shield) — directional

Ohio commercial Anthem members (Community Insurance Company / Anthem Blue Cross and Blue Shield in Ohio) follow CC-0188. Ohio Medicaid (ODM / Gainwell SPBM) is a separate program that had a January 7, 2026 P&T meeting carve-back-in for Wegovy for the MACE and MASH indications — but that applies to Ohio fee-for-service Medicaid, not to Anthem commercial. [Ohio commercial criteria — [NOT VERIFIED] to an Ohio-specific Anthem commercial bulletin in this pass.]

Georgia (Blue Cross Blue Shield of Georgia) — directional

Georgia commercial Anthem members (Blue Cross Blue Shield of Georgia) follow CC-0188. Georgia Medicaid is a separate program where Wegovy and Zepbound are absent from the May 2026 Statewide PDL and Peach State Health Plan (Centene / Ambetter, not Anthem) explicitly excludes weight-loss drugs. [Georgia commercial criteria — [NOT VERIFIED] to a BCBSGA-specific commercial bulletin in this pass.]

CarelonRx PBM administration — what this means for prescribers and pharmacies

CarelonRx (formerly IngenioRx) is Elevance Health's wholly-owned PBM, rebranded in 2023. For most Anthem commercial members, CarelonRx is the pharmacy adjudicator at point-of-sale. Key operational points:

• PA through CarelonRx, not through Anthem Medical. For pharmacy-benefit prescriptions (the majority of GLP-1 claims), the PA request goes to CarelonRx — not to Anthem Medical. The PA forms and fax numbers on Anthem's provider portal may route to CarelonRx rather than the Anthem medical director.
• CarelonRx formulary vs CC-0188 criteria. CC-0188 sets the clinical floor; CarelonRx makes independent formulary decisions (preferred / non-preferred / prior authorization / quantity limit / step therapy) that operate at point-of-sale. A drug can technically pass CC-0188 clinical criteria but still be rejected at the pharmacy counter if the plan's formulary has additional restrictions. Always check the CarelonRx formulary search at carelonrx.com for your plan's benefit design.
• Retail vs mail-order quantity limits. CarelonRx typically applies longer supply limits at mail-order / home delivery (90-day supply) than at retail (30-day supply). For a weekly GLP-1 like Wegovy or Zepbound, a 90-day supply = 13 pens; a 30-day supply = 4–5 pens. [Exact QL by drug and formulary — [NOT VERIFIED] to a specific CarelonRx published document; confirm with CarelonRx formulary search.]
• Self-funded employers customize. Large employers that self-fund their benefits can instruct CarelonRx to exclude weight-management GLP-1s entirely or add coverage with different PA criteria than the standard CarelonRx commercial formulary. Your HR benefits team or the Summary Plan Description is the authoritative source for self-funded plan design.
• CarelonRx prior authorization fax number: prescribers can initiate CarelonRx PA by contacting 1-866-776-8730 (CarelonRx PA line, subject to change) or through the electronic PA portal at carelonrx.com. Always verify the current contact on the Anthem/CarelonRx provider portal — these numbers change after rebranding events.

Appeal process — internal + external review

If Anthem or CarelonRx denies your GLP-1 PA, the standard commercial-plan appeal process applies. Key timelines and steps:

1. Request the written denial letter. The Explanation of Benefits (EOB) or denial notice must specify the clinical criterion your submission failed to satisfy — for example, “BMI documentation not provided,” “behavioral program documentation less than required duration,” or “step therapy not met.” This letter is the roadmap for your appeal.
2. File the first-level internal appeal. Commercial-plan members have the right to a first-level internal appeal. Under ACA-compliant plans, the deadline is at least 180 days from the denial date (some plans offer longer windows). Include: Letter of Medical Necessity from your prescriber, documented BMI measurement and date, comorbidity diagnoses with ICD-10 codes, behavioral program documentation (dates, provider, modalities), and — if step-therapy applies — documentation of the prior drug trial with inadequate response or contraindication.
3. Second-level internal appeal (if available). Some Anthem plans offer a two-level internal appeal. If available, escalate to the second level before requesting external review.
4. External review (IRO). If the internal appeal is denied, request an external review through an independent review organization (IRO). External review is available to all ACA-compliant commercial plans and to ERISA self-funded plans subject to applicable state law (some self-funded plans are exempt from state-mandated external review but may have contractual external review rights). External review decisions are binding on Anthem and CarelonRx.
5. State insurance department complaint. If external review rights are unavailable or exhausted, fully-insured commercial plan members can file a complaint with the state insurance commissioner in the state where the Anthem subsidiary issued the policy. Many state departments have expedited review processes for medically urgent appeals.

Use our GLP-1 PA letter generator to draft the Letter of Medical Necessity. The generator embeds the standard CC-0188 BMI and behavioral-program criteria, the SELECT-trial MACE pathway, and the SURMOUNT OSA pathway as options.

What to do if you're denied

The most common reasons Anthem commercial GLP-1 PAs are delayed or denied — and the practical fix for each:

• Missing or insufficient behavioral program documentation. Anthem CC-0188 requires documented participation in a comprehensive behavioral and dietary program. “I was told to diet and exercise by my doctor” is not sufficient — the chart needs dates, duration, and program components. The fix: ask your prescriber to write a note with the specific dates of counseling, modalities (dietitian, behavior therapy, structured lifestyle program), and duration.
• Zepbound denied as “step not met.” On formulary codes where Wegovy is CarelonRx preferred, Zepbound requires a Wegovy step or semaglutide contraindication. If you have a semaglutide contraindication (e.g., MEN 2 history, personal history of medullary thyroid carcinoma, prior severe GI reaction to a GLP-1), document it in the PA letter explicitly.
• BMI documented at the wrong date or threshold. BMI must be documented on a specific date; interpolated or estimated values are rejected. The BMI documentation in the PA packet needs to come from a clinical visit note with the date, measured height and weight, and calculated BMI.
• Employer plan exclusion. If your employer self-funds and has excluded weight-management GLP-1s, the standard internal appeal process still applies — but you are appealing a plan design decision, not a clinical decision. The fix here is typically escalating to HR and requesting an employer plan design change for the next benefits period, or pursuing cash-pay options.
• Wrong PA pathway for the indication. If you have established cardiovascular disease (prior MI, stroke, ASCVD), document the MACE pathway explicitly (BMI ≥ 27, established CVD — no weight-loss milestone required for this indication). This bypass route is available for Wegovy and is frequently overlooked.

While the appeal is in flight, many patients use cash-pay compounded semaglutide or tirzepatide as a bridge. For our verified telehealth provider directory, see best semaglutide providers and best tirzepatide providers.

Anthem Medicare Advantage and the CMS GLP-1 Bridge

Anthem Medicare Advantage (MA-PD) plans operate under Medicare Part D rules — which historically excluded weight-loss drugs under the statutory exclusion at 42 U.S.C. § 1395w-102(e)(2)(A). Key Medicare-specific points for Anthem MA-PD members:

• Wegovy MACE pathway (NOW): per the March 2024 CMS HPMS guidance, Wegovy can be covered under Part D when prescribed for cardiovascular risk reduction in patients with established CVD and BMI ≥ 27. This is available today — prior to the Bridge — on most Anthem MA-PD plans that have elected to add this indication.
• Zepbound OSA pathway (NOW): Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity is a non-weight-loss indication and can be covered under Part D. Coverage is plan-specific.
• CMS Medicare GLP-1 Bridge (07/01/2026 — 12/31/2027): effective July 1, 2026, Anthem MA-PD members gain a time-limited weight-loss coverage path. Drugs included: Wegovy (all formulations), Zepbound KwikPen only (vials and single-dose pens excluded), Foundayo (all formulations). Saxenda is excluded. Eligibility: BMI ≥ 27 plus heart disease or prediabetes. Copay: $50/month flat. The $50 copay does not count toward the deductible or the $2,100 out-of-pocket cap. The bridge ends December 31, 2027.

Anthem Medicare Advantage members who are denied a GLP-1 PA have the right to a Medicare Part C/D coverage determination, redetermination, reconsideration (through the Qualified Independent Contractor), and ALJ hearing under the standard Medicare appeals framework. See our Medicare Part D coverage guide for the full appeal chain.

Excluded plans — Anthem Medicaid

Anthem Medicaid (Anthem Whole Health Connection and its state subsidiaries) operates under each state's Preferred Drug List, not under CC-0188. Coverage for GLP-1 weight-loss drugs varies dramatically by state:

• Virginia Medicaid (Anthem HealthKeepers Plus): BMI > 40, or BMI > 37 with dyslipidemia or hypertension — verified primary source above.
• California Medi-Cal (Anthem Blue Cross): Weight-loss GLP-1s excluded effective January 1, 2026; MACE and MASH indications covered — verified primary source above.
• Georgia Medicaid (Anthem Georgia): Weight-loss GLP-1s not covered on the statewide PDL or on Anthem Medicaid Georgia's CMO formulary. See our Georgia Medicaid GLP-1 coverage article.
• Indiana Medicaid (Anthem Indiana Medicaid): Weight-loss GLP-1s excluded for adults under 405 IAC 5-24-3(b)(1); EPSDT pediatric carve-in for under-21. See our Indiana Medicaid GLP-1 coverage article.
• Other states: coverage varies. Check your specific state Medicaid PDL before filing any Anthem Medicaid GLP-1 PA.

Anthem vs Aetna vs Cigna — commercial PA guide comparison

This article is the third in the commercial-insurer PA guide triplet (Aetna → Cigna → Anthem). Key comparison points:

For the Aetna detail, see our Aetna GLP-1 PA guide. For the Cigna detail, see our Cigna GLP-1 PA guide. For the UnitedHealthcare detail (the largest commercial insurer), see our UHC GLP-1 PA guide — CDG CS10028.1, OptumRx January 2025 Wegovy-preferred formulary update, CDG CS10191 for Foundayo, NY + MA state mandate overrides, and the UHC Medicare Advantage GLP-1 Bridge. The quadruplet is now complete.

Anthem vs state Medicaid — commercial payer parallel

Anthem operates as both a commercial insurer (the 14-state Blue Cross licensee) AND a Medicaid managed care organization in 10+ states. This dual role means the same Anthem brand can mean radically different GLP-1 coverage depending on whether a member is on a commercial plan or a Medicaid plan.

The commercial PA guide triplet (Aetna + Cigna + Anthem) mirrors the architecture of our 20-state Medicaid series — both document the primary-source PA criteria from the largest payers in each segment. Key structural differences:

• Commercial plans (CC-0188 / CarelonRx): BMI ≥ 30 or ≥ 27 + comorbidity, 3-month behavioral program, ~5% continuation. Near-FDA-label-aligned criteria.
• Medicaid plans (state PDLs): criteria range from exclusion (Indiana, Georgia — all adults) to the Virginia BMI > 40 floor to California MASH-only carve-in. Driven by state budget decisions and CMS optional-benefit rules under 42 U.S.C. § 1396r-8(d)(2)(A).
• Medicare Advantage (CMS Bridge): beginning 07/01/2026, the Bridge provides a path for members with established CVD or prediabetes at $50/month.

For the full 20-state Medicaid series, start with our GLP-1 insurance coverage: Medicare, Medicaid, and commercial overview.

Verification log and [NOT VERIFIED] flags

Three Anthem primary source documents were verified by direct URL retrieval on 2026-05-10:

• CC-0188 (07/01/2024) at files.providernews.anthem.com/5083/CC-0188_Pub-07-01-2024-(redline).pdf — verified HTTP 200.
• CA Medi-Cal GLP-1 Coverage Considerations (11/14/2025) at providers.anthem.com/docs/gpp/california-provider/CA_MMP_GLP1Coverage.pdf — verified HTTP 200.
• VA CAID Weight-Loss Management PA Form at providers.anthem.com/docs/gpp/VA_CAID_WeightLossMgmtPAForm.pdf — verified HTTP 200.

The following items are [NOT VERIFIED] in this article because they could not be confirmed to a specific published clause in this pass:

• Verbatim text of CC-0188 adult PA criteria (paraphrase only in this article; obtain the document directly for verbatim language before submitting a PA).
• CarelonRx specific Wegovy preferred/Zepbound step-therapy bulletin (structural inference from Caremark analog; confirm at carelonrx.com formulary search for your plan code).
• Initial approval period length for Anthem commercial Wegovy (7 months? 8 months? Confirm with your subsidiary's current PA form).
• Continuation threshold for Saxenda on Anthem commercial (4% per Aetna, 5% per Cigna — Anthem CC-0188 specific threshold unverified).
• Foundayo (orforglipron) PA bulletin — no Anthem primary source as of 2026-05-10.
• State-specific PA forms for CA commercial, NY (Empire), OH, GA, IN, MO, CO, CT, KY, ME, NV, NH, WI commercial subsidiaries — these exist and may have state-specific criteria; not extracted in this pass.